ReciBioPharm Partners With Acuitas Therapeutics to Provide Rapid Technology Transfers & cGMP Manufacture of LNP Formulations

ReciBioPharm, the advanced and emerging therapies business unit within Recipharm, and biotechnology firm Acuitas Therapeutics have recently announced they are taking their partnership to the next level, and are ready to perform technology transfers and cGMP manufacturing for customers licensing Acuitas’ lipid nanoparticle (LNP) formulations for mRNA-based therapeutics and vaccines.

ReciBioPharm first partnered with Acuitas Therapeutics in May of 2022 as Arranta Bio (now part of ReciBioPharm) and has since transferred and manufactured multiple Acuitas LNP formulations for planned clinical trials around the globe. While initial work with Acuitas has been supporting clinical demand, ReciBioPharm’s facility and quality systems are commercially ready for fast and flexible progression of advanced therapeutics.

“This collaboration has enabled a number of Acuitas partners to rapidly progress from concept to clinic due to Acuitas’ deep process and analytical experience and our flexible development capability and strong cGMP execution,” said Nathaniel Youndt, VP of Business Strategy and Program Management at ReciBioPharm. “We look forward to continuing our work together and, with Acuitas’ licensed customer base, to bringing new mRNA-based therapeutics to patients.”

“At Acuitas, we have a commitment to excellence and a high standard for quality control for our proprietary delivery technology and the ReciBioPharm team has the same dedication to the manufacturing and transfer of our LNP,” added Chris Barbosa, Vice President of Technology Development. “We are proud to call them our partners and look forward to the continuation of this positive business relationship.”

Ongoing work with Acuitas is being performed at ReciBioPharm’s US Center of Excellence for Nucleic Acids – an 80,000-sq-ft facility in Watertown, MA, with 10,000 sq ft of process development labs, 5,000 sq ft of analytical labs, and 13 cGMP production suites. ReciBioPharm provides a comprehensive nucleic acid solution under one roof at its Watertown site, producing E. coli plasmid cell banks, CGMP plasmid DNA, multiple types of RNA drug substances, and LNP formulations with sterile fill-finish.

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals and biologics in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. For more information, visit www.recipharm.com.

Vancouver-based Acuitas Therapeutics is a private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. Acuitas partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical trials and the marketplace. The team works with global partners to develop new therapies to address unmet clinical needs based on the internationally recognized capabilities of its proprietary delivery technology. Acuitas Therapeutics’ lipid nanoparticle technology is used in the Pfizer-BioNTech COVID-19 vaccine COMIRNATY. The Acuitas team is currently working on therapeutics focused on addressing cancer, HIV/AIDS, tuberculosis, malaria, and other serious diseases. For more information, visit www.acuitastx.com.